West Pharmaceutical Services, Inc. (NYSE:WST) Stock Holdings Lessened by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. reduced its holdings in West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) by 18.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 6,356 shares of the medical instruments supplier’s stock after selling 1,426 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in West Pharmaceutical Services were worth $2,981,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Invesco Ltd. lifted its position in West Pharmaceutical Services by 14.0% in the 3rd quarter. Invesco Ltd. now owns 1,260,099 shares of the medical instruments supplier’s stock valued at $534,963,000 after purchasing an additional 154,534 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in West Pharmaceutical Services by 42.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 515,148 shares of the medical instruments supplier’s stock valued at $218,701,000 after purchasing an additional 153,180 shares during the last quarter. Brown Advisory Inc. lifted its position in West Pharmaceutical Services by 8.5% in the 4th quarter. Brown Advisory Inc. now owns 1,338,591 shares of the medical instruments supplier’s stock valued at $627,811,000 after purchasing an additional 105,397 shares during the last quarter. Marshall Wace LLP lifted its position in West Pharmaceutical Services by 60.4% in the 3rd quarter. Marshall Wace LLP now owns 249,099 shares of the medical instruments supplier’s stock valued at $105,753,000 after purchasing an additional 93,783 shares during the last quarter. Finally, WCM Investment Management LLC lifted its position in West Pharmaceutical Services by 5.0% in the 4th quarter. WCM Investment Management LLC now owns 1,514,826 shares of the medical instruments supplier’s stock valued at $710,469,000 after purchasing an additional 72,006 shares during the last quarter. Institutional investors own 91.24% of the company’s stock.

Several brokerages recently weighed in on WST. William Blair reiterated an “outperform” rating on shares of West Pharmaceutical Services in a research report on Tuesday, February 22nd. StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Monday, April 18th. Finally, Zacks Investment Research cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $450.00 target price on the stock. in a research note on Saturday, January 8th.

West Pharmaceutical Services stock opened at $349.77 on Friday. The stock has a market cap of $26.01 billion, a price-to-earnings ratio of 40.20, a PEG ratio of 4.27 and a beta of 1.06. The company has a current ratio of 2.93, a quick ratio of 2.30 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $390.14 and its two-hundred day moving average price is $409.30. West Pharmaceutical Services, Inc. has a 52 week low of $318.63 and a 52 week high of $475.35.

West Pharmaceutical Services (NYSE:WSTGet Rating) last announced its quarterly earnings data on Thursday, February 17th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.92 by $0.12. The company had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $710.20 million. West Pharmaceutical Services had a net margin of 23.37% and a return on equity of 31.20%. The business’s revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.34 EPS. Research analysts expect that West Pharmaceutical Services, Inc. will post 9.28 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 4th. Stockholders of record on Wednesday, April 20th will be paid a $0.18 dividend. The ex-dividend date of this dividend is Tuesday, April 19th. This represents a $0.72 annualized dividend and a dividend yield of 0.21%. West Pharmaceutical Services’s dividend payout ratio is currently 8.28%.

In other news, VP Quintin J. Lai sold 8,016 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $371.69, for a total value of $2,979,467.04. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.66% of the company’s stock.

West Pharmaceutical Services Company Profile (Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Stories

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.